Trials / Completed
CompletedNCT01928537
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Traws Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after treatment with azacitidine or decitabine.
Conditions
- Myelodysplastic Syndromes
- Refractory Anemia With Excess Blasts
- Chronic Myelomonocytic Leukemia
- Cytopenia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rigosertib sodium |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2017-06-29
- Completion
- 2017-06-29
- First posted
- 2013-08-26
- Last updated
- 2020-06-30
Locations
35 sites across 8 countries: United States, Australia, Denmark, France, Germany, Italy, Spain, Sweden
Source: ClinicalTrials.gov record NCT01928537. Inclusion in this directory is not an endorsement.